Programmable genetics gets more cash as Tessera Therapeutics gets a $230 million infusion – TechCrunch
Tessera Therapeutics, the Boston-based spin-up from Flagship Pioneering, is the latest company to enter the mix with $230 million in new financing to build up its platform for better biological programming. The thesis is similar to the approach taken by companies like Senti Bio, another early-stage biotech company that raised $105 million earlier this month. The company asserts that this represents a breakthrough in genetic engineering, which can build better therapies. Gene writing is inspired by and builds upon the shoulders of nature’s most prevalent class of genes: mobile genetic elements. The company said it can also write entirely new sequences into the genome by delivering only RNA.